Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06146725
Other study ID # MEC-2020-0812-3
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date January 1, 2029

Study information

Verified date November 2023
Source Erasmus Medical Center
Contact Jasper Gerritsen, MD PhD
Phone +31107036130
Email j.gerritsen@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.


Description:

Trial design This is an international, multicenter, prospective, observational, 2-arm cohort study (registration: clinicaltrials.gov ID number TBA). Eligible patients are treated with either resection or biopsy with a 3:1 ratio with a sequential computer-generated random number as subject ID. Study objectives The primary study objective is to evaluate safety and efficacy of resection versus biopsy in HGG patients as measured by overall survival (OS) and receipt of adjuvant treatment with chemotherapy and radiotherapy. Secondary study objectives are to evaluate postoperative neurological morbidity, progression-free survival (PFS), postoperative quality of life and SAEs after resection or biopsy as measured by NIHSS deteriration, tumor progression on MRI scans, quality of life questionnaires (QLQ C30, EORTC QLQ BN20, EQ 5D), and recording SAEs respectively. Study setting and participants Patients will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium. Study patients are allocated to either the supramaximal or maximum safe resection group and will undergo evaluation at presentation (baseline) and during the follow-up period at 6 weeks, 3 months, 6 months and 12 months postoperatively. Motor function will be evaluated using the NIHSS (National Institute of Health Stroke Scale) scale. Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). Patient functioning with be assessed with the Karnofsky Performance Scale (KPS) and the ASA (American Society of Anesthesiologists) physical status classification system. Health-related quality of life (HRQoL) will be assessed with the EORTC QLQ C30, EORTC QLQ BN20 and EQ 5D questionnaires. Overall survival and progression-free survival will be assessed at 12 months postoperatively. We expect to complete patient inclusion in 4 years. The estimated duration of the study (including follow-up) will be 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 564
Est. completion date January 1, 2029
Est. primary completion date January 1, 2028
Accepts healthy volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Age =18 years and =90 years 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon 3. Written informed consent Exclusion Criteria: 1. Tumors of the cerebellum, brainstem or midline 2. Medical reasons precluding MRI (e.g. pacemaker) 3. Inability to give written informed consent 4. Secondary high-grade glioma due to malignant transformation from low-grade glioma 5. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin

Study Design


Intervention

Procedure:
Tumor resection
Maximal safe resection of the tumor
Tumor biopsy
Biopsy of the tumor

Locations

Country Name City State
Belgium University Hospital Leuven Leuven
Germany University Hospital Heidelberg Heidelberg
Germany Technical University Munich Munich Bavaria
Netherlands Erasmus Medical Center Rotterdam Zuid-Holland
Netherlands Haaglanden Medical Center The Hague
Switzerland Inselspital Universitätsspital Bern Bern
United States Massachusetts General Hospital Boston Massachusetts
United States University of California, San Francisco San Francisco California

Sponsors (8)

Lead Sponsor Collaborator
Jasper Gerritsen Haaglanden Medical Centre, Insel Gruppe AG, University Hospital Bern, Massachusetts General Hospital, Technical University of Munich, Universitaire Ziekenhuizen KU Leuven, University Hospital Heidelberg, University of California, San Francisco

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Netherlands,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Time from diagnosis to death from any cause Up to 5 years postoperatively
Primary Adjuvant treatment with chemotherapy and radiotherapy Proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy after surgery 6 months postoperatively
Secondary Progression-free survival Time from diagnosis to disease progression (occurrence of a new tumor lesions with a volume greater than 0.175 cm3, or an increase in residual tumor volume of more than 25%) or death, whichever comes first Up to 5 years postoperatively
Secondary Neurological morbidity at 6 weeks NIHSS deterioration of 1 point or more at 6 weeks after surgery 6 weeks postoperatively
Secondary Neurological morbidity at 3 months NIHSS deterioration of 1 point or more at 3 months after surgery 3 months postoperatively
Secondary Neurological morbidity at 6 months NIHSS deterioration of 1 point or more at 6 months after surgery 6 months postoperatively
Secondary Quality of life at 6 weeks (EORTC QLQ C30) Quality of life as assessed by the EORTC QLQ C30 questionnaire 6 weeks postoperatively
Secondary Quality of life at 3 months (EORTC QLQ C30) Quality of life as assessed by the EORTC QLQ C30 questionnaire 3 months postoperatively
Secondary Quality of life at 6 months (EORTC QLQ C30) Quality of life as assessed by the EORTC QLQ C30 questionnaire 6 months postoperatively
Secondary Quality of life at 6 weeks (EORTC QLQ BN20) Quality of life as assessed by the EORTC QLQ BN20 questionnaire 6 weeks postoperatively
Secondary Quality of life at 3 months (EORTC QLQ BN20) Quality of life as assessed by the EORTC QLQ BN20 questionnaire 3 months postoperatively
Secondary Quality of life at 6 months (EORTC QLQ BN20) Quality of life as assessed by the EORTC QLQ BN20 questionnaire 6 months postoperatively
Secondary Quality of life at 6 weeks (EQ-5D) Quality of life as assessed by the EQ-5D questionnaire 6 weeks postoperatively
Secondary Quality of life at 3 months (EQ-5D) Quality of life as assessed by the EQ-5D questionnaire 3 months postoperatively
Secondary Quality of life at 6 months (EQ-5D) Quality of life as assessed by the EQ-5D questionnaire 6 months postoperatively
Secondary Serious Adverse Events Serious Adverse Events within 6 weeks postoperatively 6 weeks postoperatively
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs